NCT04029090View on ClinicalTrials.gov

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

October 20, 2018

Study Completion Date

October 23, 2018

Conditions
Healthy Adult Subjects
Interventions
DRUG

MCI-186

A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.

DRUG

MCI-186

A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.

DRUG

Placebo

A single dose of 0.9% w/v saline over 60 min will be intravenously administered.

Trial Locations (1)

Unknown

Investigational site, Tokyo

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY